Tenax Therapeutics (TENX) Net Cash Flow (2010 - 2026)

Tenax Therapeutics (TENX) has 17 years of Net Cash Flow data on file, last reported at $21.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 27.94% year-over-year to $21.2 million; the trailing twelve-month figure through Mar 2026 stood at $7.3 million (down 92.57% YoY), and the FY2025 full-year result was $2.7 million, down 96.81% from the prior year.
• Net Cash Flow grew to $21.2 million in Q1 2026, from -$1.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $88.9 million in Q3 2024 to a low of -$6.1 million in Q3 2025.
• A 5-year average of $6.7 million and a median of -$1.7 million in 2022 frame the typical range for Net Cash Flow.
• Peak annual rise in Net Cash Flow reached 4047.46% in 2024, while the deepest fall reached 210.2% in 2024.
• Tracing TENX's Net Cash Flow over 5 years: stood at -$1.7 million in 2022, then climbed by 19.81% to -$1.3 million in 2023, then sank by 155.21% to -$3.4 million in 2024, then jumped by 48.05% to -$1.8 million in 2025, then surged by 1284.46% to $21.2 million in 2026.
• Business Quant data shows TENX's Net Cash Flow at $21.2 million in Q1 2026, -$1.8 million in Q4 2025, and -$6.1 million in Q3 2025.